Skip to Content

GSK plc Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, Aug. 11, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises GSK plc (“GSK” or the “Company”) (NYSE: GSK) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. GSK investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email:, to discuss their legal rights, or click here to join the case via The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

On August 9, 2022, Vir Biotechnology, Inc. (“Vir”), GSK’s development partner for the proposed COVID-19 treatment sotrovimab, issued a press release disclosing that that Vir “and GSK do not plan to file a Biologics License Application for sotrovimab at this time and do not intend to pursue the US-based Phase 3 COMET-STAR prophylaxis trial. Discussions with the FDA remain ongoing regarding the appropriate path forward for sotrovimab in the US.” On this news, GSK’s American Depositary Receipt price fell $1.73 per share or 4.32% percent, to close at $38.30 per share on August 10, 2022.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar

Attorney Advertising

Primary Logo